Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

239

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Gastroesophageal Reflux

Interventions

DRUG

Zegerid

20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.

DRUG

Losec

20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.

Trial Locations (1)

Department of Gastroenterology and Hepatology, Oncology Centre, Roentgena, Warsaw